Oct. 2018: Allergan (Stock to Study), CVS Health (Undervalued)

The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan plc (NYSE: AGN) as its October 2018 "Stock to Study" and CVS Health Corporation (NYSE: CVS) as its October 2018 "Undervalued Stock" for investors' informational and educational use.

"The committee selected Allergan for its low price-earnings ratio relative to recent history and the potential for P/E expansion when the company's product pipeline becomes more apparent," said Adam Ritt, editor of BetterInvesting Magazine. "For the Undervalued selection, the committee cited CVS's pending merger with Aetna as a catalyst for increased growth as well as its new home-delivery service to compete with Amazon's recent entry into the business."

Check BetterInvesting's October issue for more details about these selections. Go to the trial version of BetterInvesting's online tools to study the investment potential of Allergan and CVS by viewing their fundamental data and applying judgments.

Committee members are Robert M. Bilkie, Jr., CFA; Daniel J. Boyle, CFA; Marisa Bradbury, CFA; Philip S. Dano, CFA; Maury Elvekrog, CFA; Walter J. Kirchberger, CFA; and Adam Ritt.

As stated, the BetterInvesting committee's Stock to Study and Undervalued Stock choices are for the informational and educational uses of investors and are not intended as investment recommendations. BetterInvesting urges investors to educate themselves about the stock market so they can make informed decisions about stock purchases.